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Summary
Background and objectives Several factors might alter serum phosphate homeostasis and induce hyperhos-
phatemia in patients with chronic kidney disease (CKD) not requiring dialysis. However, whether and to
what extent hyperphosphatemia is associated with a poor prognosis in different CKD patient groups re-
main to be elucidated.
Design, setting, participants & measurements We utilized the “Prevenzione Insufficienza Renale Progres-
siva” (PIRP) database, a large project sponsored by the Emilia-Romagna Health Institute. PIRP is a collabor-
ative network of nephrologists and general practitioners located in the Emilia-Romagna region, Italy, aimed
at increasing awareness of CKD complications and optimizing CKD patient care. We identified 1716 pa-
tients who underwent a GFR and serum phosphorous assessment between 2004 and 2007. We tested
whether phosphate levels 4.3 mg/dl are associated with the risk of CKD progression or all causes of
death.
Results Older age and male sex were associated with lower phosphate levels. Instead, higher phosphate lev-
els were noted in patients with diabetes. Patients with phosphate levels 4.3 mg/dl were at an increased
risk of starting dialysis or dying (hazard ratio 2.04; 95% confidence interval [1.44, 2.90]). Notably, subgroup
analyses revealed that the magnitude of the risk associated with hyperphosphatemia varied depending on
age, sex, diabetes, and different stages of CKD.
Conclusions These analyses lend support to the hypothesis that phosphorous abnormalities might have a
negative effect on the residual renal function and prognosis in different groups of CKD patients. However,
the risk associated with hyperphosphatemia might vary in specific CKD patient subgroups.
Clin J Am Soc Nephrol 6: ●●●–●●●, 2011. doi: 10.2215/CJN.07810910
Introduction
Over the past 10 years a growing body of evidence
has been built up suggesting a link between serum
levels of bone minerals, vitamin D, intact parathy-
roid hormones (iPTH), the cardiovascular system,
and mortality. These associations were first de-
tected in large data sets of patients on dialysis (1–3)
and only recently have similar links been confirmed
in chronic kidney disease (CKD) not requiring di-
alysis (4) and in people with normal kidney func-
tion (5–8).
Nonetheless, despite a large and convincing body
of evidence suggesting a robust association between
serum phosphorous levels and all-cause mortality in
dialysis-dependent individuals, (2,3) only a few pa-
pers have investigated the adverse effects of hyper-
phosphatemia on kidney function and prognosis in
CKD individuals (9–14). Notably, these papers did
not test whether the toxicity associated with hyper-
phosphatemia is quantitatively or qualitatively differ-
ent in men and women, persons with diabetes, the
elderly, and different stages of CKD. Indeed, serum
phosphorus is under the control of three dynamically
interacting factors: diet intake, the net amount re-
moved by the bone, and the quota excreted by the
kidneys. Several experimental and observational
studies suggest that the relative contribution of these
factors to hyperphosphatemia may vary in different
subgroups of individuals. Thus, the higher levels of
serum phosphorus reported in women, persons with
diabetes, and young individuals may reflect different
pathologic conditions and may be associated with a
different prognostic significance. In this regard, two
previous papers by Onufrak and co-workers (6,15)
suggest that the adverse effect of serum phosphorus
on the cardiovascular system and mortality might be
limited to men from the general population (6,15).
We sought to investigate the robustness of the as-
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sociation between hyperphosphatemia and progression to
ESRD as well as all-cause mortality in the overall study
cohort and in different subgroups of CKD patients not
receiving dialysis.
Materials and Methods
Patients
We used the patient records from the “Prevenzione In-
sufficienza Renale Progressiva” (PIRP) database, a large
project sponsored by the Emilia-Romagna Health Institute.
The PIRP project is a collaborative network of nephrolo-
gists and general practitioners located in the region of
Emilia-Romagna, Italy, aimed at increasing awareness of
CKD complications and optimizing CKD patient care. De-
mographic, clinical, and laboratory characteristics of all
consecutive patients referred to a nephrology center are
added to the PIRP database. From the original database,
we identified all of the patients who underwent a GFR
(estimated GFR) and serum phosphorous assessment from
the date the PIRP project began (July 2004) to the last
available update of the list of deaths of the “Agenzia
Sanitaria e Sociale Regionale- Regione Emilia-Romagna.”
This agency provided the PIRP investigators with the of-
ficial list of patients registered in the PIRP data set who
died during the follow-up (from July 2004 to December
2007).
The diabetes classification was based on having either an
8-hour fasting plasma glucose level 126 mg/dl, a non-
fasting plasma glucose200 mg/dl, or whether the patient
reported having diabetes or was taking diabetes medica-
tions. Hypertension was defined as a diastolic BP 90
mmHg, systolic pressure 140 mmHg, or self-report of
taking medication for hypertension. Chronic obstructive
pulmonary disease (COPD) was defined if the patient re-
ported having COPD. Cardiovascular disease (CVD) was
defined as a history of cardiac arrhythmia, peripheral vas-
cular disease, cerebral vasculopathy, ischemic heart dis-
ease, or chronic heart failure.
Laboratory Methods
Measurement of serum phosphorus, creatinine, and
other biomarkers was performed at the time of PIRP proj-
ect inception in a fasting state at each study site. All of the
laboratories used a serum creatinine analysis calibrated
against an isotope dilution mass spectrometry (IDMS) ref-
erence standard. The estimated GFR (eGFR) was deter-
mined through the Modification of Diet in Renal Disease
(MDRD) equation for standardized serum creatinine val-
ues (16).
Due to the fact that the PIRP is a collaborative project
with the general practitioners in the Emilia-Romagna re-
gion rather than an observational study, parathyroid hor-
mone and 25OH vitamin D levels were not standardized
and were not included in the analysis.
Study Outcomes
For this study we examined the association between
phosphorus and three outcomes: (1) the composite event of
progression to ESRD or death, whichever came first; (2)
progression to ESRD defined as the need for renal replace-
ment therapy; (3) all-cause mortality. Indeed, these are the
most clinically relevant outcomes for CKD patients. None-
theless, considering the association between fast renal
function deterioration and risk of death, (17) it is important
to test the effect of phosphorus on the combination of the
two outcomes before testing the effect of phosphorus on
each of the two outcomes separately. Furthermore, the
association between phosphorus and outcome was tested
in different CKD patient subgroups. Clinical outcome ad-
judication is systematically performed at 6 monthly inter-
vals. The date of dialysis inception is identified through the
Italian Registry of Dialysis or, alternatively, by the renal
unit where the patient started RRT. Deaths among cohort
members are identified through the review of the official
list of deaths provided by the Italian local government
agency “Agenzia Sanitaria e Sociale Regionale- Regione
Emilia-Romagna”, as well as by means of a regular fol-
low-up by the physician at each study site.
Statistical Analyses
As serum phosphorus does not seem to be linearly as-
sociated with the clinical outcome (Figure 1B) and the risk
of clinical outcome increases significantly for serum phos-
phorus above the 75th percentile of the serum distribution,
the patients were grouped into four strands based upon
quartile of serum phosphorus at baseline. Continuous de-
mographic, clinical, laboratory variables are presented as
mean and SD or median and interquartile range (IQ) when
appropriate. Categorical variables are expressed as propor-
tions. Trends across quartiles of phosphorus were com-
pared using ANOVA for continuous variables and 2 tests
for discrete variables. To gauge the association between
serum phosphorus and the primary end point, we first
plotted the incidence of the composite end point curves
according to phosphorus quartiles using the Kaplan-Meier
product-limit method and we used the two-sided log rank
test to calculate overall P value for survival differences
(18). Next, we calculated the age and multivariable ad-
justed hazard ratios (HR) by fitting the data to Cox pro-
portional hazard models (19).
The robustness of the association between serum phos-
phorus and clinical outcome was tested by progressively
adding variables to the models that might have an effect on
serum phosphorus or the clinical outcome considered. All
of the models presented are age-adjusted, case mix–ad-
justed (adjusted for age, sex, eGFR, history of diabetes
mellitus, history of hypertension, and history of COPD and
CVD), and lastly, fully adjusted (age  case mix  hemo-
globin, total calcium, uric acid and ACE inhibitors, vitamin
D, and calcium salts use). We tested all of the variables to
ensure they satisfied the proportional hazards assumption.
The model’s predictive performance was internally vali-
dated by means of a nonparametric bootstrapping process
(20,21). The effect modification of variables that could
modulate the association between hyperphosphatemia and
the composite outcome was explored by performing sub-
group analyses and by inclusion of interaction terms. In
view of the relatively small number of events in each
subgroup and the competitive nature of the two end points
studied, we did not separately test the association between
hyperhosphatemia and the two end points. Case deletion
was used to handle the missing values. A P value 0.05
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was considered statistically significant. All analyses were
completed using R version 2.9.2 (August 24, 2009) (The R
Foundation for Statistical Computing).
Results
The characteristics of the 1716 participants are sum-
marized in Table 1. Greater levels of phosphorus were
noted in women and in young patients as well as in
association with diabetes mellitus, severe renal impair-
ment, low levels of serum calcium and hemoglobin, and
with the use of vitamin D and calcium salts (Table 1).
During an average follow-up of 1.3  0.94 (median
1.15, IQ 0.59 to 1.91) years, 451 patients died or pro-
gressed to ESRD and began dialysis (composite end
point rate: 202 of 1000 patients-year, 95% confidence
interval [CI]: 184, 221). Specifically, 178 patients died
(mortality rate: 97 of 1000 patients-year, 95% [CI]: 84,
113) and 273 started dialysis (dialysis initiation rate: 137
of 1000 patients-year, 95% CI: 121, 154).
The cumulative incidence of the composite end point
(death or dialysis inception) in the overall population
differed significantly by phosphorus quartiles (log-rank
Figure 1. | (A) Overall likelihood of experiencing the composite end point according to quartile of serum phosphorus. (B) The HR of
experiencing the composite end point according to serum phosphorous levels adjusted for age, case mix, hemoglobin, total calcium, uric acid
and ACE inhibitors, vitamin D, and calcium salts use. The solid line represents the HR according to serum phosphorous level; the grey area
represents the 95% CI.
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test: P  0.001, for all tests) (Figure 1A). Indeed, when
compared with the mid-low quartile of phosphorus
(phosphorous level 3.3 mg/dl and 3.8 mg/dl), a
serum level of phosphorus 3.3 mg/dl was associated
with the lowest risk (age-adjusted HR: 0.64, 95% CI:
[0.42, 0.96]; P  0.03) of experiencing the composite end
point. In contrast, a serum phosphorous level 4.3
mg/dl was associated with a significant increase in the
risk in the composite end point (HR: 4.01, 95% CI: 2.93,
5.47; P  0.001) (Table 2).
We then adjusted for the casemix (i.e., sex, eGFR, history of
diabetes mellitus, history of hypertension, and history of
COPD and CVD) and the risk of the composite end point was
attenuated but remained significantly elevated among pa-
tients in the highest quartile of phosphorus (HR 2.32; 95% CI:
1.64, 3.27; P  0.001). By contrast, patients in the lowest
quartile of phosphorus did not show a significant reduction
in the incidence of the composite end point (HR 0.75; 95% CI:
0.49, 1.14; P 0.18) (Table 2). Noteworthy, further adjustment
for different modifiable factors associated with either pro-
gression to dialysis or mortality (i.e., hemoglobin, total cal-
cium, uric acid and ACE inhibitors, vitamin D, and calcium
salts use) did not substantially change the hazard associ-
ated with hyperphosphatemia (HR 2.04; 95% CI: 1.44,
2.90; P  0.001) (Table 2).
Despite the fact that the analyses for the interaction terms did
not reveal any statistically significant modification, with the
exception of diabetes (significant interaction P  0.02), the sub-
group analyses revealed that the hyperphosphatemia magni-
tude of effect might also vary depending on age, sex, and
different stages of CKD (Figure 2). Indeed, a serum phos-
phorous level above the normality range (i.e., 4.3 mg/dl)
seems to predict a greater risk of the composite end point
in earlier stages of CKD in men, the elderly, and patients
with diabetes (Figure 2).
We then separately tested the association between serum
phosphate and the risk of death or progression to dialysis.
As expected, patients with hyperphosphatemia (phospho-
rus 4.3 mg/dl) were more likely than peers to experience
each of the two events (Figures 3 and 4). Indeed, after
adjustments for confounders, serum levels of phosphorus
4.3 mg/dl was associated with a significant 188% (HR
2.88; CI 1.77, 4.67; P  0.001) and 149% (HR 2.49; 95% CI
1.44, 4.32; P  0.001) increase in the risk of either starting
dialysis or of death, respectively (Figures 3 and 4, Table 3).
Finally, we performed a bootstrap analysis to further
examine the strength of the association between phos-
phorus and the primary end point. The results yielded
by this technique confirmed the prognostic validity of
the serum phosphorous variable in terms of risk predic-
tion of progression to ESRD or death. Indeed, serum
phosphate was selected in almost all of the Cox models
calculated with the bootstrap samples. Furthermore, the
bootstrap procedure only marginally modified the haz-
ard of the composite end point and the confidence in-
terval associated with hyperphosphatemia (HR 2.04;
95% CI: 1.54, 2.69). Similar findings were also noted for
the association between phosphorus and the risk of pro-
gression to ESRD (HR 2.86; 95% CI: 1.93, 4.32) or death
(HR 1.73; 95% CI: 1.12, 2.77).
Discussion
Our results lend further support to the notion that
serum phosphorus is linked to an adverse effect on renal
function and prognosis in CKD, independently of other
traditional risk factors (22,23). Indeed, progressive ad-
justment for confounders as well as the bootstrap anal-
Figure 2. | Association between hyperphosphatemia (serum phos-
phorus >4.3 mg/dl) and the composite outcome (death or progres-
sion to ESRD) in different CKD-NDD subgroups. Here are depicted
the HR associated with hyperphosphatemia compared with the refer-
ence group (serum phosphorus3.3 but3.8 mg/dl) in different stages
of CKD, age category, sex, and diabetes status. All results are adjusted
for the case mix and hemoglobin, total calcium, uric acid, ACE inhib-
itors, vitamin D, and calcium salts use.
Table 2. Association between hyperphosphatemia and the composite outcome (death or progression to ESRD) in the study cohort
Overall (n  1716)
Variable
Age-Adjusted Case Mix Modela Cox Full Modelb
HR 95% CI P HR 95% CI P HR 95% CI P
P  3.3 mg/dl 0.64 0.42 to 0.96 0.03 0.75 0.49 to 1.14 0.18 0.78 0.51 to 1.19 0.25
P  3.3 and  3.8 Ref Ref Ref
P  3.8 and  4.3 1.29 0.91 to 1.81 0.14 0.98 0.69 to 1.39 0.94 0.93 0.66 to 1.33 0.72
P  4.3 4.01 2.93 to 5.47 0.001 2.32 1.64 to 3.27 0.001 2.04 1.44 to 2.90 0.001
aCase mix: age  gender, eGFR, history of diabetes mellitus, history of hypertension, and history of COPD and CVD.
bFull model: age  case mix  hemoglobin, total calcium, uric acid and ACE inhibitors, vitamin D, and calcium salts use.
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yses confirmed that hyperphosphatemia predicts a rapid
deterioration in residual renal function and poor prog-
nosis in CKD patients. Our results are in line with and
extend previous reports (9–14) by suggesting that the
risk burden associated with hyperphosphatemia might
vary in different patient subgroups.
A number of different hormones and factors interact
to maintain phosphate homeostasis through the con-
certed action of the intestine, kidneys, and skeleton.
Indeed, sex hormones, parathyroid hormone, vitamin D,
and fibroblast growth factor 23 (FGF-23) and its co-
receptor Klotho are probably only a few of the factors
that tightly regulate intestinal absorption, incorporation
in the skeleton, and/or renal excretion of phosphorus
(24,25). Furthermore, if these mechanisms are thought to
chronically regulate phosphorous metabolism, there is
now evidence of a bowel-kidney cross talk responsible
for the excretion of acutely accrued dietary phosphorus
Figure 3. | Overall likelihood of progression to end-stage renal disease and dialysis inception according to the serum phosphorous quartile.
Figure 4. | Overall likelihood of all causes of death according to the serum phosphorous quartile.
6 Clinical Journal of the American Society of Nephrology
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loads (24). Consequently, hyperphosphatemia might re-
sult from different imbalances in phosphorous metabo-
lism.
Our findings suggest that the risk associated with a
serum phosphorous level 4.3 mg/dl appears substan-
tially larger in men than in women despite the fact that
women tended to exhibit higher phosphate levels than
men. Two previous papers have suggested similar gender
heterogeneity in the association of serum phosphorus with
atherosclerosis as well as with incident coronary artery
disease and all-cause mortality (6,15). The reasons for such
a discrepancy might be explained by the lower basal haz-
ard in women as compared with that in men or, possibly,
by the complex interplay between sex hormones and phos-
phorous homeostasis. Although the mechanisms are not
completely understood, experimental studies have demon-
strated that estrogens reduce PTH transcription and vita-
min D activation as well as increase FGF-23 circulating
levels (26). All of these factors contribute to regulating the
renal tubular phosphate reabsorption capacity and might
explain the lower phosphorous excretion observed in
women than in men reported by Cirillo and co-workers
(27). Furthermore, estrogen circulating levels also modu-
late bone turnover and calcium and phosphorous bone
removal (26). Thus, renal tubular reabsorption and bone
removal might account for the difference in serum phos-
phorous levels and for the paradoxical finding of a lower
phosphorous toxicity in women as compared with that in
men.
The subgroup analyses also suggest that in more ad-
vanced stages of CKD and in older age groups hyperphos-
phatemia might not predict renal function deterioration or
death. Indeed, after adjustment for demographic, comor-
bidity, and laboratory factors, the association between hy-
perphosphatemia and risk of the composite end point was
attenuated to the extent of losing statistical significance.
Undeniably, these findings might be due to a selection bias
in that patients prone to phosphorus toxicity do not sur-
vive CKD or die younger. Furthermore, older CKD pa-
tients are less likely than younger CKD patients to progress
to ESRD, weaken the association between phosphorus and
the composite end point of all causes of death, or progres-
sion to ESRD. Nevertheless, a number of biologic consid-
erations deserve to be mentioned. Indeed, with aging, the
daily dietary phosphorous intake is reduced (28) and it
increases the quota of phosphorus excreted by the kidney
(27). Thus, we can speculate that the accumulation of phos-
phorus in the body slowly diminishes throughout the life-
time (27). Thus, it is biologically plausible that the differ-
ence in the strength of the association between
hyperphosphatemia and outcome in the elderly might be
put down to a different phosphorous balance in the differ-
ent age groups.
Finally, we detected a significant increase in phospho-
rous toxicity in patients with diabetes when compared
with that in nondiabetic controls. Diabetes might be asso-
ciated with profound and deleterious effects on parathy-
roid cells and osteocytes (29). In a large series of 602 CKD
patients, Tanaka and co-workers have shown an indepen-
dent association between diabetes and high phosphate lev-
els as well as low PTH, FGF-23, and vitamin D levels (29).
The consequent expansion of the phosphorus pool, cou-
pled with a poor vitamin D status, might contribute to
acceleration of arterial function and structure deterioration
as well as explain the excessive risk of all-cause mortality
associated with hyperphosphatemia in patients with dia-
betes (30,31).
However, this study has several limitations that ought to
be pointed out. First, as PIRP is not an observational study
but a collaborative network with the general practitioners,
there is no study protocol. Hence, data incompleteness and
lack of standardization of some biochemical parameters
are the major weakness of the current results. For these
reasons, PTH and vitamin D levels were not included in
the analysis. However, given the complicated interplay
and colinearity among these factors, we believe that ad-
justing for PTH and vitamin D levels might not substan-
tially change our results. Second, aged, hypertensive CKD
patients mainly constitute the study cohort and it might
not be possible to generalize the results to the entire CKD
population. Nonetheless, these are the patients who are
currently mostly referred to nephrologists. Third, a base-
line assessment does not allow for discrimination between
hyperphosphatemia because of an acute or chronic impair-
ment of phosphorous metabolism. Nevertheless, such het-
erogeneity should dilute the effect and bias our results
toward the null. Fourth, we did not account for time-
varying changes in serum phosphorus. However, consid-
ering that serum phosphorus represents only 1% of the
total stores, it is unlikely that these analyses could help in
determining the total amount of phosphorus in the body or
the net phosphorous balance which we believe may poten-
tially explain the modulation of the adverse effect of hy-
perphospatemia in different subgroups of CKD patients.
Fifth, renal function was not measured but rather calcu-
lated by means of the MDRD equation; thus, a potential
misclassification of CKD stages might have occurred, es-
pecially in the very old patients and more advanced stages
of CKD. Finally, the observational nature of this study does
not allow us to assess the causal relationship between
hyperphosphatemia and poor prognosis, so future studies
should assess whether serum phosphate lowering im-
proves survival in CKD patients.
Conclusions
Our results underscore a robust association between
serum phosphorus and a rapid decline in renal function
and mortality. Nonetheless, subgroup analyses showed
that the relative contribution of hyperphosphatemia in pre-
dicting progression to ESRD or death might differ between
women, persons with diabetes, older patients, and those in
more severe stages of CKD. Thus, these results suggest that
the definition of hyperphosphatemia should be tailored to
the individual patient group. Future studies should test
whether interventions aimed at achieving different phos-
phorous targets improves survival in different subgroups
of CKD patients.
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